Cargando…

Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis

There is an increasing number of trauma patients presenting on pre-injury antiplatelet (AP) agents attributable to an aging population and expanding cardio- or cerebrovascular indications for antithrombotic therapy. The effects of different AP regimens on outcomes after traumatic brain injury (TBI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, François, Malhotra, Armaan K., Ku, Jerry C., Zeiler, Frederick A., Wilson, Jefferson R., Pirouzmand, Farhad, Scales, Damon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438446/
https://www.ncbi.nlm.nih.gov/pubmed/36060453
http://dx.doi.org/10.1089/neur.2022.0042
_version_ 1784781826089287680
author Mathieu, François
Malhotra, Armaan K.
Ku, Jerry C.
Zeiler, Frederick A.
Wilson, Jefferson R.
Pirouzmand, Farhad
Scales, Damon C.
author_facet Mathieu, François
Malhotra, Armaan K.
Ku, Jerry C.
Zeiler, Frederick A.
Wilson, Jefferson R.
Pirouzmand, Farhad
Scales, Damon C.
author_sort Mathieu, François
collection PubMed
description There is an increasing number of trauma patients presenting on pre-injury antiplatelet (AP) agents attributable to an aging population and expanding cardio- or cerebrovascular indications for antithrombotic therapy. The effects of different AP regimens on outcomes after traumatic brain injury (TBI) have yet to be elucidated, despite the implications on patient/family counseling and the potential need for better reversal strategies. The goal of this systematic review and meta-analysis was to assess the impact of different pre-injury AP regimens on outcomes after TBI. In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the OVID Medline, Embase, BIOSIS, Scopus, and Cochrane databases were searched from inception to February 2022 using a combination of terms pertaining to TBI and use of AP agents. Baseline demographics and study characteristics as well as outcome data pertaining to intracerebral hematoma (ICH) progression, need for neurosurgical intervention, hospital length of stay, mortality, and functional outcome were extracted. Pooled odds ratios (ORs) and mean differences comparing groups were calculated using random-effects models. Thirteen observational studies, totaling 1244 patients receiving single AP therapy with acetylsalicylic acid or clopidogrel, 413 patients on dual AP therapy, and 3027 non-AP users were included. No randomized controlled trials were identified. There were significant associations between dual AP use and ICH progression (OR, 2.81; 95% confidence interval [CI], 1.19–6.61; I(2), 85%; p = 0.02) and need for neurosurgical intervention post-TBI (OR, 1.61; 95% CI, 1.15–2.28; I(2), 15%; p = 0.006) compared to non-users, but not between single AP therapy and non-users. There were no associations between AP use and hospital length of stay or mortality after trauma. Pre-injury dual AP use, but not single AP use, is associated with higher rates of ICH progression and neurosurgical intervention post-TBI. However, the overall quality of studies was low, and this association should be further investigated in larger studies.
format Online
Article
Text
id pubmed-9438446
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-94384462022-09-02 Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis Mathieu, François Malhotra, Armaan K. Ku, Jerry C. Zeiler, Frederick A. Wilson, Jefferson R. Pirouzmand, Farhad Scales, Damon C. Neurotrauma Rep Original Article There is an increasing number of trauma patients presenting on pre-injury antiplatelet (AP) agents attributable to an aging population and expanding cardio- or cerebrovascular indications for antithrombotic therapy. The effects of different AP regimens on outcomes after traumatic brain injury (TBI) have yet to be elucidated, despite the implications on patient/family counseling and the potential need for better reversal strategies. The goal of this systematic review and meta-analysis was to assess the impact of different pre-injury AP regimens on outcomes after TBI. In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the OVID Medline, Embase, BIOSIS, Scopus, and Cochrane databases were searched from inception to February 2022 using a combination of terms pertaining to TBI and use of AP agents. Baseline demographics and study characteristics as well as outcome data pertaining to intracerebral hematoma (ICH) progression, need for neurosurgical intervention, hospital length of stay, mortality, and functional outcome were extracted. Pooled odds ratios (ORs) and mean differences comparing groups were calculated using random-effects models. Thirteen observational studies, totaling 1244 patients receiving single AP therapy with acetylsalicylic acid or clopidogrel, 413 patients on dual AP therapy, and 3027 non-AP users were included. No randomized controlled trials were identified. There were significant associations between dual AP use and ICH progression (OR, 2.81; 95% confidence interval [CI], 1.19–6.61; I(2), 85%; p = 0.02) and need for neurosurgical intervention post-TBI (OR, 1.61; 95% CI, 1.15–2.28; I(2), 15%; p = 0.006) compared to non-users, but not between single AP therapy and non-users. There were no associations between AP use and hospital length of stay or mortality after trauma. Pre-injury dual AP use, but not single AP use, is associated with higher rates of ICH progression and neurosurgical intervention post-TBI. However, the overall quality of studies was low, and this association should be further investigated in larger studies. Mary Ann Liebert, Inc., publishers 2022-08-10 /pmc/articles/PMC9438446/ /pubmed/36060453 http://dx.doi.org/10.1089/neur.2022.0042 Text en © François Mathieu et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mathieu, François
Malhotra, Armaan K.
Ku, Jerry C.
Zeiler, Frederick A.
Wilson, Jefferson R.
Pirouzmand, Farhad
Scales, Damon C.
Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
title Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
title_full Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
title_fullStr Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
title_full_unstemmed Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
title_short Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
title_sort pre-injury antiplatelet therapy and risk of adverse outcomes after traumatic brain injury: a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438446/
https://www.ncbi.nlm.nih.gov/pubmed/36060453
http://dx.doi.org/10.1089/neur.2022.0042
work_keys_str_mv AT mathieufrancois preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis
AT malhotraarmaank preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis
AT kujerryc preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis
AT zeilerfredericka preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis
AT wilsonjeffersonr preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis
AT pirouzmandfarhad preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis
AT scalesdamonc preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis